INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 160 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41 | +78.3% | 1,900 | +35.7% | 0.00% | +33.3% |
| Q2 2023 | $23 | +15.0% | 1,400 | +133.3% | 0.00% | +50.0% |
| Q1 2023 | $20 | -13.0% | 600 | -40.0% | 0.00% | 0.0% |
| Q4 2022 | $23 | -100.0% | 1,000 | -94.4% | 0.00% | -95.1% |
| Q3 2022 | $590,000 | +15.9% | 18,000 | +50.0% | 0.04% | +17.1% |
| Q2 2022 | $509,000 | -2.5% | 12,000 | +0.9% | 0.04% | +29.6% |
| Q1 2022 | $522,000 | +1907.7% | 11,894 | +2873.5% | 0.03% | +2600.0% |
| Q4 2021 | $26,000 | -51.9% | 400 | -74.0% | 0.00% | -50.0% |
| Q3 2021 | $54,000 | -97.0% | 1,540 | -95.7% | 0.00% | -97.6% |
| Q2 2021 | $1,829,000 | +4843.2% | 36,000 | +1252.4% | 0.08% | +2733.3% |
| Q2 2018 | $37,000 | -64.4% | 2,662 | -59.4% | 0.00% | -66.7% |
| Q1 2018 | $104,000 | +160.0% | 6,562 | -19.0% | 0.01% | +800.0% |
| Q4 2017 | $40,000 | -77.0% | 8,098 | -74.7% | 0.00% | -83.3% |
| Q3 2017 | $174,000 | +411.8% | 31,976 | +657.5% | 0.01% | +500.0% |
| Q2 2017 | $34,000 | – | 4,221 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |